1. Yuen MF, Chen DS, Dusheiko GM, et al. Hepatitis B virus infection. Nat Rev Dis Primers.2018;4:18035.
2. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology.2015;148(1):221-244 e223.
3. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis.2019;78(6):736-745.
4. Ramos-Casals M, Brito-Zeron P, Bombardieri S, et al. EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies. Ann Rheum Dis.2020;79(1):3-18.
5. Fasano S, Gordon P, Hajji R, Loyo E, Isenberg DA. Rituximab in the treatment of inflammatory myopathies: a review. Rheumatology (Oxford).2017;56(1):26-36.
6. Rodriguez-Pinto I, Cervera R, Espinosa G. Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome. Ther Adv Musculoskelet Dis.2015;7(1):26-30.
7. Tieu J, Smith R, Basu N, et al. Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. Rheumatology (Oxford).2020;59(4):e24-e32.
8. Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis.2020;79(6):685-699.
9. Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology.2015;61(2):703-711.
10. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology.2018;67(4):1560-1599.
11. Kuo MH, Tseng CW, Lee CH, Tung CH, Tseng KC, Lai NS. Moderate Risk of Hepatitis B Virus Reactivation in HBsAg(-)/HBcAb(+) Carriers Receiving Rituximab for Rheumatoid Arthritis. Sci Rep.2020;10(1):2456.
12. Chen YM, Chen HH, Huang WN, et al. Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation. Int J Rheum Dis.2019;22(6):1145-1151.
13. Tien YC, Yen HH, Li CF, et al. Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study. Arthritis Res Ther.2018;20(1):246.
14. Varisco V, Vigano M, Batticciotto A, et al. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study. J Rheumatol.2016;43(5):869-874.
15. van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB. Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years. J Rheumatol.2015;42(10):1761-1766.
16. Barone M, Notarnicola A, Lopalco G, et al. Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. Hepatology.2015;62(1):40-46.
17. Ni YH, Chang MH, Wu JF, Hsu HY, Chen HL, Chen DS. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol.2012;57(4):730-735.
18. Loomba R, Liang TJ. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology.2017;152(6):1297-1309.
19. Koutsianas C, Thomas K, Vassilopoulos D. Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. Ther Adv Musculoskelet Dis.2020;12:1759720X20912646.
20. Fukuda W, Hanyu T, Katayama M, et al. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan. Ann Rheum Dis.2017;76(6):1051-1056.
21. Raimondo G, Locarnini S, Pollicino T, et al. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol.2019;71(2):397-408.
22. Hsu HY, Chang MH, Ni YH, Chiang CL, Wu JF, Chen HL. Universal infant immunization and occult hepatitis B virus infection in children and adolescents: a population-based study. Hepatology.2015;61(4):1183-1191.
23. Ghaziasadi A, Fakhari Z, Aghcheli B, et al. High prevalence of occult hepatitis B infection (OBI) among healthy children and their parents in Alborz province, Iran; Vertical OBI, myth or truth? Liver Int.2020;40(1):92-100.
24. Hsu HY, Chang MH, Ni YH, et al. Chronologic changes in serum hepatitis B virus DNA, genotypes, surface antigen mutants and reverse transcriptase mutants during 25-year nationwide immunization in Taiwan. J Viral Hepat.2017;24(8):645-653.
25. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis.2002;2(8):479-486.
26. Hsu CY, Ko CH, Wang JL, Hsu TC, Lin CY. Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study. Arthritis Res Ther.2019;21(1):211.
27. Chen HC, Chung CH, Wang CH, et al. Increased risk of sudden sensorineural hearing loss in patients with hepatitis virus infection. PLoS One.2017;12(4):e0175266.
28. Md Yusof MY, Vital EM, McElvenny DM, et al. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol.2019;71(11):1812-1823.
29. Chen MH, Chen MH, Liu CY, et al. Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Biologics Treatment. J Infect Dis.2017;215(4):566-573.
30. Wong GL, Wong VW, Yuen BW, et al. Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure. J Hepatol.2020;72(1):57-66.